Immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease

Hiroyuki Naruse, Hiroyasu Ito, Hideo Izawa, Masayoshi Sarai, Junnichi Ishii, Eirin Sakaguchi, Reiko Murakami, Tatsuya Ando, Hidetsugu Fujigaki, Kuniaki Saito

研究成果: Article査読

抄録

Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD−IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD−IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD−IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection.

本文言語English
論文番号5498
ジャーナルJournal of Clinical Medicine
10
23
DOI
出版ステータスPublished - 01-12-2021

All Science Journal Classification (ASJC) codes

  • 医学(全般)

フィンガープリント

「Immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル